Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Women with a history of the malignancy also survive longer than men after receiving a liver transplant.
A Rhode Island study found that testing for hepatitis C among people on probation is likely a good way to find undiagnosed individuals.
Initial 12-week results of a 48-week treatment period showed the drug led to a significant decline in weight and liver enzymes.
An analysis of newly diagnosed youths in California found they had limited access to opioid-related harm reduction services.
Sustained response to direct-acting antivirals prolonged survival by a year and a half.
HCV incidence in a Canadian study was lower than rates seen in some European countries.
A pair of studies found that bacteriophage therapy may treat alcoholic hepatitis and primary sclerosing cholangitis.
In a Phase II study, the drug was safe and well tolerated, and a small number of people achieved benchmarks of success against the virus.
People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
In a Phase IIa trial, the drug DUR-928 was associated with numerous positive outcomes after 28 days.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.
Adults with chronic liver disease are more than twice as likely than those without the condition to have barriers to medical care.
Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.
A new classification system may more accurately reflect liver-related death trends in the United States.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.